{
    "documentMetadata": {
        "title": "Staphylococcal Scalded Skin Syndrome",
        "sourceFile": "Staphylococcal Scalded Skin Syndrome.pdf",
        "lastUpdated": "2023-02-28"
    },
    "content": [
        {
            "type": "header",
            "level": 1,
            "text": "Clinical Setting"
        },
        {
            "type": "list",
            "items": [
                "Staphylococcal Scalded Skin Syndrome (SSSS) is a toxin-mediated infection of the skin caused by hematogenous spread of a strain of S. aureus that produces an exfoliative toxin.",
                "Arises from a focus of infection with an exotoxin-producing S. aureus strain, including impetigo, bacterial conjunctivitis, or wounds; may also occur in the setting of invasive S aureus infection (e.g., pneumonia, septic arthritis, endocarditis)",
                "More common in children than adults; SSSS occurs in immunocompromised adults; Drug-induced Stevens Johnson Syndrome/toxic epidermal necrolyis (SJS/TEN) is more common in adults.",
                "Can complicate varicella in children.",
                "Diagnosis usually made clinically via history and physical exam",
                "Culture suspected sites of infection to identify S. aureus and obtain susceptibility data"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Etiologies"
        },
        {
            "type": "list",
            "items": [
                "Result of hematogenous spread S. aureus that produces an exfoliative toxin.",
                "Pathogen maybe MSSA or MRSA"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Primary Regimens"
        },
        {
            "type": "list",
            "items": [
                "Fluids and supportive care in the hospital",
                "Empiric antibiotic therapy active vs. both MSSA and MRSA until culture results available: e.g, Vancomycin.",
                "No data on theoretical benefit of protein synthesis inhibitor, e.g., Clindamycin, to inhibit toxin production, though some experts recommend adding clindamycin in severely ill patients.",
                "MSSA:",
                "Adults: (Nafcillin or Oxacillin) 2 gm IV q4h",
                "Pediatric: (Nafcillin or Oxacillin) 150 mg/kg/day IV divided q6h",
                "MRSA:",
                "Adults: Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 \u00b5g/mL x hr (see vancomycin AUC dosing calculator); alternative target is trough of 15-20 \u00b5g/mL",
                "Pediatric: Vancomycin 60-80 mg/kg IV divided 3-4 times a day for target AUC24 400 \u00b5g/mL x hr (see vancomycin AUC dosing calculator)",
                "Note: traditional dosing of 45-60 mg/kg/day frequently does not achieve target AUC in term infants and older children with normal renal function. Use of AUC24 closer to 400 \u00b5g/mL adequate for most non-CNS infections. Clin Infect Dis Jul 13 2020"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Alternative Regimens"
        },
        {
            "type": "list",
            "items": [
                "None"
            ]
        },
        {
            "type": "header",
            "level": 1,
            "text": "Comments"
        },
        {
            "type": "list",
            "items": [
                "Most often seen in children.",
                "References: Am J Clin Dermatol 4:165, 2003; Clin Infect Dis 42:181, 2006; Br J Dermatol. 2019;181(1):37. Epub 2019 Apr 25; Pediatric Dermatology 2021; 38(1): 149."
            ]
        }
    ]
}